SCHEMBL3671699

SCHEMBL3671699

O=C1CCCN1c1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 1.00
ROCK2 O75116 5/20 0.66
CDK2 P24941 4/20 0.66
PRKACA P17612 4/20 0.66
GSK3B P49841 3/20 0.66
AURKA O14965 3/20 0.66
MAPK13 O15264 3/20 0.66
DAPK3 O43293 3/20 0.66
JAK2 O60674 3/20 0.66
CHEK2 O96017 3/20 0.66
PRKCG P05129 3/20 0.66
CDK1 P06493 3/20 0.66
MARK3 P27448 3/20 0.66
MAPK1 P28482 3/20 0.66
CSNK1D P48730 3/20 0.66
MAPKAPK2 P49137 3/20 0.66
MAPK12 P53778 3/20 0.66
CSNK2A1 P68400 3/20 0.66
CDK5 Q00535 3/20 0.66
PRKCD Q05655 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291919 0.80 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4297910 0.80 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4293715 0.80 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL3665675 0.78 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL3673460 0.78 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4300162 0.74 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4289886 0.74 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4286354 0.74 CDC7 (1.00) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL3671042 0.73 CDC7 (0.78) CDC7ROCK2CDK2PRKACAGSK3B
SCHEMBL4284801 0.73 CDC7 (0.77) CDC7ROCK2CDK2PRKACAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN claimed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.